Presseportal.ch - MoonLake Immunotherapeutics AGhttps://www.presseportal.ch/de/nr/100084813?langid=2Presseportal.ch: MoonLake Immunotherapeutics AG (Newsroom)de-denews aktuell schweiz AGhttps://www.presseportal.ch/images/logos/logo-ch-250.jpgPresseportal.ch - MoonLake Immunotherapeutics AGhttps://www.presseportal.ch/de/nr/100084813?langid=2info@newsaktuell.ch (presseportal.ch)Thu, 21 May 2026 07:02:39 +0200Thu, 24 Mar 2022 08:00:54 +0100MoonLake Immunotherapeutics AG6MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpointMoonLake Immunotherapeutics AG: Zug, Switzerland (ots/PRNewswire) - - This Phase 2 study represents an important step in hidradenitis suppurativa ("HS") clinical development, as it will be the first to use the higher clinical response level of HiSCR75 as the primary endpoint - ...https://www.presseportal.ch/de/pm/100084813/100886974?langid=2Thu, 24 Mar 2022 08:00:54 +0100https://www.presseportal.ch/de/pm/100084813/100886974?langid=2 MoonLake Immunotherapeutics AG [Newsroom]
Zug, Switzerland (ots/PRNewswire) - - This Phase 2 study represents an important step in hidradenitis suppurativa ("HS") clinical development, as it will be the first to use the higher clinical response level of HiSCR75 as the primary endpoint - ... Lesen Sie hier weiter...

]]>Wirtschaftinfo@newsaktuell.ch (presseportal.ch)MoonLake Immunotherapeutics AG